论文部分内容阅读
目的观察恩替卡韦联合安络化纤丸治疗乙肝后肝硬化失代偿期近期疗效。方法将48例乙肝后肝硬化失代偿期患者在患者知情同意的基础上随即分成对照组24例,治疗组24例。对照组给予恩替卡韦0.5mg/d口服,治疗组给予安络化纤丸6g/次、每日3次加恩替卡韦0.5mg/d口服,疗程均48周。观察治疗前后患者肝功能、凝血酶原活动度(PTA)、肝纤维谱、HBeAg转阴率、HBV-DNA定量水平、Child-Pugh评分变化情况。结果 2组在治疗前后肝功能、Child-Pugh评分、凝血酶原活动度、HBeAg转阴率、HBV-DNA定量水平比较差异有显著性(P<0.01),2组治疗后肝纤维谱比较差异有显著性(P<0.01)。结论恩替卡韦联合安络化纤丸可迅速抑制HBV-DNA复制,改善乙肝后肝硬化失代偿期患者肝脏纤维化,促进肝功能恢复。
Objective To observe the short-term curative effect of entecavir combined with Anluo Huaxian Wan on the treatment of decompensated liver cirrhosis. Methods Forty-eight patients with decompensated hepatitis B after liver cirrhosis were randomly divided into control group (24 cases) and treatment group (24 cases) on the basis of informed consent. Control group was given entecavir 0.5mg / d orally, the treatment group was given Anluo Huaxiang Wan 6g / times, 3 times daily entecavir 0.5mg / d orally, the course of treatment were 48 weeks. The changes of liver function, prothrombin activity (PTA), hepatic fibrosis, HBeAg negative rate, HBV-DNA level and Child-Pugh score were observed before and after treatment. Results Before and after treatment, liver function, Child-Pugh score, prothrombin activity, HBeAg negative rate and HBV-DNA quantitative level were significantly different between the two groups (P <0.01). There was significant difference between the two groups There was significant (P <0.01). Conclusion Entecavir combined with Anluohuaxu pill can rapidly inhibit HBV-DNA replication, improve hepatic fibrosis in patients with decompensated hepatitis B and promote recovery of liver function.